BofA/Merrill Lynch Upgrades Myriad Genetics (MYGN) to Buy
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.05 +0.66%
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $25.37 yesterday.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $25.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
- Why this Wall Street strategist says the "trade is long gold"
- BofA says used equipment values remain stable in July
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
